Nektar Therapeutics (ITH0) Income Statement
Nektar Therapeutics Income Statement
Last quarter (Q2 2026), Nektar Therapeutics's total revenue was $10.13M, a decrease of 9.34% from the same quarter last year. In Q2, Nektar Therapeutics's net income was $-40.62M. See Nektar Therapeutics’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 55.23M | $ 98.43M | $ 90.12M | $ 92.06M | $ 101.91M | |
| $ 55.23M | $ 67.74M | $ 53.48M | $ 70.42M | $ 77.01M | |
| $ 186.00M | $ 172.94M | $ 190.90M | $ 310.66M | $ 523.11M | |
| Depreciation and Amortization | $ 1.03M | $ 4.39M | $ 7.82M | $ 13.03M | $ 14.15M |
| $ -137.00M | $ -86.70M | $ -243.11M | $ -323.04M | $ -461.82M | |
| $ -130.77M | $ -105.20M | $ -137.43M | $ -240.24M | $ -446.10M | |
| $ -33.44M | $ -14.00M | $ -138.83M | $ -124.75M | $ -77.18M | |
| $ -164.21M | $ -119.20M | $ -276.26M | $ -364.98M | $ -523.28M | |
| $ -164.08M | $ -118.96M | $ -276.06M | $ -368.20M | $ -523.84M | |
| Per Share Metrics | |||||
| Basic EPS | $ -9.73 | $ -8.68 | $ -21.79 | $ -29.51 | $ -42.90 |
| Diluted EPS | $ -9.73 | $ -8.68 | $ -21.79 | $ -29.51 | $ -42.90 |
| Weighted Average Shares Outstanding | 16.87M | 13.71M | 12.67M | 12.48M | 12.22M |
| Weighted Average Shares Outstanding (Diluted) | 16.87M | 13.71M | 12.67M | 12.48M | 12.22M |
Currency in USD